Great Valley Advisor Group’s DexCom DXCM Stock Holding History

Great Valley Advisor Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,960	Closed	-$402K	–	442
2020 Q2	$402K	Buy	+3,960	New	+$354K	0.07%	270

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Great Valley Advisor Group's DXCM Position: Q3 2020 in Review

Great Valley Advisor Group sold out of DexCom (DXCM) in Q3 2020, closing a stake of 3,960 shares — an estimated $402K sold.

Great Valley Advisor Group first reported a position in DXCM in Q2 2020 and held it in 1 quarter. The position peaked at $402K in Q2 2020. 727 funds tracked by Wall St. Rank hold DXCM as of Q3 2020.

Great Valley Advisor Group reported no remaining DexCom position as of Q3 2020 after selling out during the quarter.
Great Valley Advisor Group sold 3,960 DexCom shares in Q3 2020, an estimated $402K.
Great Valley Advisor Group first reported a position in DexCom in Q2 2020 and held it in 1 quarter.
Great Valley Advisor Group's DexCom position peaked at $402K in Q2 2020.
727 funds tracked by Wall St. Rank held DexCom as of Q3 2020.

Based on Great Valley Advisor Group's 13F filing for Q3 2020, filed 21 Oct 2020.